Effects of the tyrosine-kinase inhibitor geldanamycin on ligand-induced Her-2/neu activation, receptor expression and proliferation of Her-2-positive malignant cell lines

International Journal of Cancer

Volumn 70, Issue 2, 1997, Pages 221-229

  Hartmann, Frank ^a,e   Horak, Eva M ^a   Cho, Cheryl ^b   Lupu, Ruth ^c   Bolen, Joseph B ^d   Stetler Stevenson, Mary A ^a   Pfreundschuh, Michael ^e   Waldmann, Thomas A ^a   Horak, Ivan D ^a,f  

^a NATIONAL CANCER INSTITUTE   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e SAARLAND UNIVERSITY   (Germany)

^f JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELDANAMYCIN; HERBIMYCIN A; MESSENGER RNA; ONCOPROTEIN; PROTEIN TYROSINE KINASE INHIBITOR;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; HUMAN; HUMAN CELL; ONCOGENE NEU; PRIORITY JOURNAL; TUMOR CELL LINE;

ADENOCARCINOMA; BENZOQUINONES; BREAST NEOPLASMS; CELL DIVISION; ENZYME ACTIVATION; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LACTAMS, MACROCYCLIC; LIGANDS; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PROTEIN-TYROSINE KINASES; QUINONES; RECEPTOR, ERBB-2; RNA, MESSENGER; RNA, NEOPLASM; TUMOR CELLS, CULTURED;

EID: 0031025859     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19970117)70:2<221::AID-IJC14>3.0.CO;2-L     Document Type: Article

References (32)

1. BELKA, C., BRACH, M.M. and HERRMANN, F., The role of tyrosine kinases and their substrates in signal transmission of hematopoietic growth factors: a short review. Leukemia, 9, 754-761 (1995).
2. BENCHEKROUN, M.N., MYERS, C.E. and SINHA, B.K., Free radical formation by ansamycin benzoquinone in human breast-tumor cells: implications for cytotoxicity and resistance. Free Radic. Biol. Med., 17, 191-200 (1994).
3. BLAGOSKLONNY, M.V., TORETSKY, J. and NECKERS, L., Geldanamycin selectively destabilizes and conformationally alters mutated p53. Oncogene, 11, 933-939 (1995).
4. BOLEN, J.B., Signal transduction by the SRC family of tyrosine protein kinases in hemopoietic cells. Cell Growth Differentiation, 2, 409-414 (1991).
5. CHAVANY, C., MIMNAUGH, E., MILLER, P., BITTON, R., NGUYEN, P., TREPEL, J., WHITESELL, L., SCHNUR, R., MOYER, J. and NECKERS, L., p185erbB2 binds to GRP94 in vivo. Dissociation of the p185erbB2/GRP94 heterocomplex by benzoquinone ansamycins precedes depletion of p185erbB2. J. biol. Chem., 271, 4974-4977 (1996).
6. CLARK, J.W., SANTOS-MOORE, A., STEVENSON, L.E. and FRACKELTON JR., A.R., Effects of tyrosine-kinase inhibitors on the proliferation of human breast-cancer cell lines and proteins important in the ras signalling pathway. Im. J. Cancer, 65, 186-191 (1996).
7. DOUGALL, W.C., QIAN, X., PETERSON, N.C., MlLLER, M.J., SAMANTA, A. and GREENE, M.I., The neu oncogene: signal-transduction pathways, transformation mechanisms and evolving therapies. Oncogene, 9, 2109-2123 (1994).
8. FANTL, W.J., JOHNSON, D.E. and WILLIAMS, L.T., Signalling by receptor tyrosine kinases. Ann. Rev. Biochem., 62, 453-481 (1993).
9. v-src activity in vitro. Biochem. biophys. Res. Commun., 173, 276-282 (1990).
10. 14C]herbimycin A and its use in the elucidation of the kinase-inactivation mechanism. FEBS Lett., 340, 155-158 (1994).
11. JUNE, C.H., FLETCHER, M.C., LEDBETTER, J.A., SCHIEVEN, G.L., SIEGEL, J.N., PHILIPS, A.F. and SAMELSON, L.E., Inhibition of tyrosine phosphorylation prevents T-cell-receptor-mediated signal transduction. Proc. nat. Acad. Sci. (Wash.), 87, 7722-7726 (1990).
12. LEVITZKI, A. and GAZTT, A., Tyrosine-kinase inhibition: an approach to drug development. Science, 267, 1782-1788 (1995).
13. LIPSICH, L.A., LEWIS, A.J. and BRUGGE, J.S., Isolation of monoclonal antibodies that recognize the transforming proteins of avian sarcoma viruses. J. Virol., 48, 352-360 (1983).
14. erbB2. Science, 249, 1552-1555 (1990).
15. LUPU, R., DICKSON, R.B. and LIPPMAN, M.E., The role of erb B-2 and its ligands in growth control of malignant breast epithelium. J. Steroid Biochem. molec. Biol., 43, 229-236 (1992).
16. MAHON, T.M. and O'NEILL, L.A., Studies into the effect of the tyrosine-kinase inhibitor herbimycin A on NF-kappa B activation in T lymphocytes. Evidence for co-valent modification of the p50 sub-unit. J. biol. Chem., 270, 28557-28564 (1995).
17. MILLER, P., DIORIO, C., MOVER, M., SCHNUR, R.C., BRUSKIN, A., CULLEN, W. and MOVER, J.D., Depletion of the erbB-2 gene product p 185 by benzoquinoid ansamycins. Cancer Res., 54, 2724-2730 (1994).
18. MURAKAMI, Y., FUKAZAWA, H., MIZUNO, S. and UEHARA, Y., Conversion of epidermal growth factor (EGF) into a stimulatory ligand for A431-cell growth by herbimycin A by decreasing the level of expression of EGF receptor. Biochem. J., 301, 57-62 (1994).
19. MURAKAMI, Y., MIZUNO, S., HORI, M. and UEHARA, Y., Reversal of transformed phenotypes by herbimycin A in src-oncogene-expressed rat fibroblasts. Cancer Res., 48, 1587-1590 (1988).
20. 1-positive-leukemia-cell growth. Blood, 80, 1330-1338 (1992).
21. SCHULTE, T.W., BLAGOSKLONNY, M.V., INGUI, C. and NECKERS, L., Disruption of the Raf-l-Hsp90 molecular complex results in destabilization of Raf-1 and loss of Rat-1-Ras association. J. biol. Chem., 270, 24585-24588 (1995).
22. SEPP-LORENZINO, L., MA, Z., LEBWOHL, D.E., VINITSKY, A. and ROSEN, N., Herbimycin A induces the 20-S-proteasome- and ubiquitin-dependent degradation of receptor tyrosine kinases. J. biol. Chem., 270, 16580-16587 (1995).
23. STEFANOVA, I., CORCORAN, M.L., HORAK, E.M., WAHL, L.M., BOHLEN, J.B. and HORAK, I.D., Lipopolysaccharide induces activation of CD 14-associated protein tyrosine kinase p53/56lyn. J. biol. Chem., 268, 20725-20728 (1993).
24. TANG, C.K., FEREZ, C., GRUNT, T., CHO, C., WAIBEL, C. and LUPU, R., Involvement of heregulin-β2 in the acquisition of the hormone-independent phenotype of breast-cancer cells. Cancer Res., 56, 3350-3358 (1996).
25. UEHARA, Y., HORU M., TAKEUCHI, T. and UMEZAWA, H., Phenotypic change from transformed to normal induced by benzoquinonoid ansamycins accompanies inactivation of p60src in rat kidney cells infected with Rous sarcoma virus. Mol. cell. Biol., 6, 2198-2206 (1986).
26. UEHARA, Y., MURAKAMI, Y., MIZUNO, S. and KAWAI, S., Inhibition of transforming activity of tyrosine-kinase oncogenes by herbimycin A. Virology, 164, 294-298 (1988).
27. v-src. Cancer Res., 49, 780-785 (1989).
28. WHITESELL, L., MIMNAUGH, E.G., DE COSTA, B., MYERS, C.E. and NECKERS, L.M., Inhibition of heat-shock-protein-HSP90-pp60v-src heleroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc. nat. Acad. Sci. (Wash.), 91, 8324-8328 (1994).
29. WHITESELL, L., SHIFRIN, S.D., SCHWAB, G. and NECKERS, L.M., Benzoquinoid ansamycins possess selective tumoricidal activity unrelated to src-kinase inhibition. Cancer Res., 52, 1721-1728 (1992).
30. YAMAKI, H., IGUCHI-ARIGA, S.M.M. and ARIGA, H., Inhibition of c-mvc gene expression in murine lymphoblastoma cells by geldanamycin and herbimycin, antibiotics of benzoquinoid ansamycin group. J. Antibiot., 42, 604-610 (1989).
31. YAMAKI, H., NAKAJIMA, M., SEIMIYA, H., SAYA, H., SUGITA, M. and TSURUO, T., Inhibition of the association with nuclear matrix of pRB, p70 and p40 proteins along with the specific suppression of c-mvc expression by geldanamycin, an inhibitor of Src tyrosine kinase. J. Antibiot., 48, 1021-1026 (1995).
32. YAMAKI, H., SUZUKI, H., CHOI, E.C. and TANAKA, N., Inhibition of DNA synthesis in murine tumor cells by geldanamycin, an antibiotic of benzoquinoid ansamycin group. J. Antibiot., 35, 886-892 (1982).